PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|October 2, 2018
Catalent Pharma Solutions
Catalent Pharma Solutions offers its partners end-to-end solutions, from drug formulation and drug delivery technologies, to manufacturing and clinical supply services.
Advertisement
Catalent Pharma Solutions offers its partners end-to-end solutions, from drug formulation and drug delivery technologies, to manufacturing and clinical supply services. Each molecule has unique characteristics, and Catalent offers partners its formulation and development experience, and a wide range of tools and technologies to create innovative, intelligent dose forms to overcome challenges, while making better products for patients.
14 Schoolhouse Rd, Somerset, NJ 08873
tel. 1.888.SOLUTION
solutions@catalent.com
AAPS Booth Number: 1727
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement